Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with...

Area of Science:

• Endocrinology
• Oncology
• Medical Diagnostics

Background:

• Differentiated thyroid carcinoma (DTC) recurrence risk stratification is crucial for patient management.
• Existing systems may not fully capture dynamic changes in disease status.
• Response to initial therapy is a key factor in predicting DTC outcomes.

Purpose of the Study:

• To describe and validate a modified dynamic risk stratification system for DTC.
• To incorporate serum anti-Tg antibody (TgAb) status into risk assessment.
• To evaluate the system's efficacy in predicting recurrence and persistence in DTC patients.

Main Methods:

• Retrospective analysis of 715 DTC patients treated between 2000-2005.
• Classification into four groups based on response to initial therapy: excellent, acceptable, biochemical incomplete, and structural incomplete.
• Inclusion of serum TgAb status in the modified risk stratification model.

Main Results:

• The modified system demonstrated significant predictive value for DTC recurrence (P<0.001 for all comparisons).
• Patients with 'structural incomplete' response had a 281.2-fold higher risk of recurrence compared to 'excellent response'.
• Disease-free survival was 98.3% for 'excellent response' versus 6.8% for 'structural incomplete response'.

Conclusions:

• The modified dynamic risk stratification system, including TgAb status, is validated for predicting DTC recurrence.
• Personalized risk assessment based on initial therapy response improves follow-up and management strategies for DTC.
• This system offers a valuable tool for tailoring patient care in differentiated thyroid carcinoma.